(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 973.96% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Argenx Se's revenue in 2025 is $4,726,086.On average, 11 Wall Street analysts forecast ARGX's revenue for 2025 to be $219,582,807,283, with the lowest ARGX revenue forecast at $195,269,310,340, and the highest ARGX revenue forecast at $236,694,307,994. On average, 11 Wall Street analysts forecast ARGX's revenue for 2026 to be $285,483,837,441, with the lowest ARGX revenue forecast at $229,099,795,978, and the highest ARGX revenue forecast at $339,539,519,031.
In 2027, ARGX is forecast to generate $356,761,361,639 in revenue, with the lowest revenue forecast at $317,658,283,196 and the highest revenue forecast at $437,617,425,382.